Effects of the new prokinetic agent DA-9701 formulated with Corydalis Tuber and Pharbitis Seed in patients with minimal change esophagitis: A bicenter, randomized, double blind, placebo-controlled study

Title
Effects of the new prokinetic agent DA-9701 formulated with Corydalis Tuber and Pharbitis Seed in patients with minimal change esophagitis: A bicenter, randomized, double blind, placebo-controlled study
Author
박찬혁
Keywords
DA-9701; Minimal change esophagitis; Motilitone; Non-erosive reflux disease
Issue Date
2014-07
Publisher
대한소화기기능성질환·운동학회
Citation
Journal of neurogastroenterology and motility,v.20 no.3, pp.338 - 346
Abstract
Background/AimsDA-9701 (Motilitone) is a new prokinetic agent formulated with Corydalis Tuber and Pharbitis Seed. We assessed the efficacy of DA-9701 in symptomatic patients with minimal change esophagitis.MethodsPatients with minimal change esophagitis presenting with reflux or dyspeptic symptoms were randomly assigned to receive either DA-9701 30 mg or placebo t.i.d. (means 3 times a day). After 4 weeks of treatment, the primary efficacy end point determined by changes of the Nepean dyspepsia index questionnaire-Korean version (NDI-K) symptom scores, was analyzed.ResultsForty-two and 39 patients were assigned to the treatment and control groups, respectively. After 4 weeks, NDI-K symptom scores were reduced from 35.4 to 13.5 (P < 0.001) and from 43.0 to 27.7 (P < 0.001) in the treatment and the control groups, respectively. However, changes in the symptom scores did not differ between the 2 groups (P = 0.741). Although the quality of life scores were significantly improved after 4 weeks in both groups, changes in the quality of life score between the baseline value and that at 4 weeks did not differ between the 2 groups. The reflux symptom score was significantly improved in the treatment group compared to the placebo group in patients aged 65 years or older (P = 0.035).ConclusionsAlthough NDI-K symptom scores and quality of life scores were improved after 4 weeks of treatment compared with baseline values in patients with minimal change esophagitis, DA-9701 did not improve the symptom scores or quality of life scores compared with the placebo.
URI
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102148/http://hdl.handle.net/20.500.11754/50848
ISSN
2093-0879; 2093-0887
DOI
10.5056/jnm14019
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > ETC
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE